Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Investment

Blue Sky scratches head lice from portfolio

Blue Sky Venture Capital has exited a head lice treatment company after it entered into a $278 million commercial agreement with Indian-based Dr. Reddy's Laboratories.

Upgrade your subscription to access this article

And gain access to:
  • All website content, including archived news
  • Home page news customisation
  • Tech Zone, your technical resource library
And more
Already A Subscriber?

Read more: Blue Sky Venture Capital,  Laboratories,  Australia,  Indian-based Dr. Reddy,  Blue Sky Private Equity,  Hatchtech,  Adelaide,  Andrew Champion,  Blue Sky Alternative Investments,  Dr Elaine Stead,  GM Hotels,  Greg Matiland,  Independent Pub Group,  Queensland Biotechnology Fund,  Uniseed,  University of Melbourne